jpoly4

Fountain Therapeutics Appoints William L. Greene, M.D. Chief Executive Officer

SOUTH SAN FRANCISCO, Calif., April 26, 2021 — Fountain Therapeutics, a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced the appointment of William L. Greene, M.D. as the company’s chief executive officer, effective April 26, 2021. Dr. Greene was appointed to the Fountain Board of Directors …

Fountain Therapeutics Appoints William L. Greene, M.D. Chief Executive Officer Read More »

Biopharma Executive Perspectives on 2021

When our backs were against the wall, the biotech/biopharma community came together to create not one, but two vaccines currently approved for emergency use in the U.S. This has earned the industry a lot of respect.

A year in Longevity: science perspectives

Over the past year, we’ve had the pleasure of speaking to some of the Longevity sector’s most influential people. From expert views on biomarkers and interventions, the definition of biological age, the secret to healthy aging, or AI and COVID-19, we’ve put together some of our favourites.

Fountain Therapeutics Moves Corporate Headquarters to Lilly Gateway Labs in South San Francisco

Fountain Therapeutics (“Fountain”), a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced it has moved its corporate headquarters to Lilly Gateway Labs in South San Francisco upon selection by Eli Lilly and Company. The company joins a select group of emerging biotech companies spearheading innovation in drug …

Fountain Therapeutics Moves Corporate Headquarters to Lilly Gateway Labs in South San Francisco Read More »

Scroll to Top